Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Merck and Pfizer Enter Worldwide Collaboration Agreement

Published: Wednesday, May 01, 2013
Last Updated: Wednesday, May 01, 2013
Bookmark and Share
Agreement to develop and commercialize ertugliflozin, an investigational medicine for type 2 diabetes.

Merck & Co., Inc., known as MSD outside the United States and Canada (“Merck”), and Pfizer Inc. have announced that they have entered into a worldwide (except Japan) collaboration agreement for the development and commercialization of Pfizer’s ertugliflozin (PF-04971729), an investigational oral sodium glucose cotransporter (SGLT2) inhibitor being evaluated for the treatment of type 2 diabetes. Ertugliflozin is Phase III ready, with trials expected to begin later in 2013.

“We are pleased to join forces with Merck in the battle against type 2 diabetes and the burden that it poses on global health,” said John Young, president and general manager, Pfizer Primary Care.

Young continued, “Through this collaboration, we believe we can build on Merck’s leadership position in diabetes care with the introduction of ertugliflozin, an innovative SGLT2 inhibitor discovered by Pfizer scientists.”

Under the terms of the agreement, Merck, through a subsidiary, and Pfizer will collaborate on the clinical development and commercialization of ertugliflozin and ertugliflozin-containing fixed-dose combinations with metformin and JANUVIA® (sitagliptin) tablets.

Merck will continue to retain the rights to its existing portfolio of sitagliptin-containing products.

Pfizer has received an upfront payment and milestones of $60 million and will be eligible for additional payments associated with the achievement of pre-specified future clinical, regulatory and commercial milestones.

Merck and Pfizer will share potential revenues and certain costs on a 60/40 percent basis.

“Merck continues to build upon our leadership position in the oral treatment of type 2 diabetes through our own research and business development,” said Nancy Thornberry, senior vice president and Diabetes and Endocrinology franchise head, Merck Research Laboratories.

Thornberry continued, “We believe ertugliflozin has the potential to complement our strong portfolio of investigational and marketed products, and we look forward to collaborating with Pfizer on its development.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More Than 4,600+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Merck, Afferent Pharmaceuticals Collaborate
Collaboration aims to acquire all outstanding stock of Afferent in exchange for an upfront payment of $500 million in cash.
Friday, June 24, 2016
Merck Acquires IOmet Pharma
Acquisition grows Merck’s oncology pre-clinical pipeline with novel IDO1 and TDO inhibitors.
Thursday, January 14, 2016
Merck and DNAtrix Announce Collaboration
Phase 2 immuno-oncology collaboration in patients with aggressive form of brain cancer.
Friday, October 09, 2015
Merck Acquires cCAM Biotherapeutics
Company enhances immuno-oncology portfolio through strategic collaborations and acquisitions.
Thursday, August 06, 2015
Merck and NanoString Announce Clinical Research Collaboration
Collaboration builds on Merck’s R&D and NanoString’s biomarker development leadership positions in immuno-oncology.
Friday, June 05, 2015
Lilly, Merck Enter Collaboration Agreement
Agreement to research immuno-oncology combination regimens in multiple types of cancer.
Friday, January 16, 2015
Merck and NewLink Genetics Enter Into Licensing and Collaboration Agreement
Clinical development, manufacturing expertise, and scale critical to success.
Tuesday, November 25, 2014
Merck Enters Strategic Collaborations with Amgen, Incyte and Pfizer
Merck also to initiate Phase I “signal finding” study with MK-3475 in 20 new cancer types.
Saturday, February 08, 2014
Elexopharm Enters Into Cardiovascular Collaboration With Merck & Co.
Agreement aims to develop and commercialize candidates targeting aldosterone synthase for the treatment of cardiovascular disease.
Wednesday, May 19, 2010
Merck Reports Initial Results of Phase III Studies with Vicriviroc in Treatment-Experienced HIV-Infected Patients
Data for investigational HIV CCR5 receptor antagonist presented at 17th conference on retroviruses and opportunistic infections.
Friday, February 19, 2010
Xenon Enters Cardiovascular Disease Collaboration with Merck
The collaboration is aimed to discover and develop novel small molecule candidates for the potential treatment of cardiovascular disease.
Thursday, June 25, 2009
Ambrx and Merck Serono Expand Collaboration through Drug Development Alliance
The global strategic collaboration aims to develop and commercialize Ambrx's ARX424 preclinical product candidate for the treatment of multiple sclerosis.
Thursday, February 26, 2009
Vical Receives Milestone Payment from Merck Triggered by Planned Initiation of Investigational Cancer DNA Vaccine Trial
Vical announces receipt of a $1.0 million milestone based on Merck's planned initiation of a Phase I clinical trial of pDNA cancer vaccine.
Tuesday, December 02, 2008
Merck Scientists Apply Innovative Research Method to Identify Changes in Gene Networks Linked to Obesity
The work provide evidence that genetic susceptibility to obesity involves changes in entire networks of genes and is not limited to mutations in several specific genes.
Tuesday, March 18, 2008
Ambrx Enters FGF-21 Type 2 Diabetes Drug Discovery Collaboration with Merck and Co.
The collaboration aims to develop a therapeutic protein with biological properties similar to Fibroblast Growth Factor 21 for the treatment of type 2 diabetes.
Thursday, December 20, 2007
Scientific News
Platelets are the Pathfinders for Leukocyte Extravasation During Inflammation
Findings from the study could help in the prevention and treatment of inflammatory pathologies.
ASMS 2016: Targeting Mass Spectrometry Tools for the Masses
The expanding application range of MS in life sciences, food, energy, and health sciences research was highlighted at this year's ASMS meeting in San Antonio, Texas.
Benchtop Automation Trends
Gain a better understanding of current interest in and future deployment of benchtop automated systems.
Manufactured Stem Cells to Advance Clinical Research
Clinical-grade cell line will enable development of new therapies and accelerate early-stage clinical research.
Dengue Virus Exposure May Amplify Zika Infection
Researchers at Imperial College London have found that the previous exposure to the dengue virus may increase the potency of Zika infection.
Gender Determination in Forensic Investigations
This study investigated the effectiveness of lip print analysis as a tool in gender determination.
Identifying Novel Types of Forensic Markers in Degraded DNA
Scientists have tried to verify the nucleosome protection hypothesis by discovering STRs within nucleosome core regions, using whole genome sequencing.
Proteins in Blood of Heart Disease Patients May Predict Adverse Events
Nine-protein test shown superior to conventional assessments of risk.
Higher Frequency of Huntington's Disease Mutations Discovered
University of Aberdeen study shows that the gene change that causes Huntington's disease is much more common than previously thought.
Starving Stem Cells May Enable Scientists To Build Better Blood Vessels
Researchers from the University of Illinois at Chicago College of Medicine have uncovered how changes in metabolism of human embryonic stem cells help coax them to mature into specific cell types — and may improve their function in engineered organs or tissues.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,600+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!